Guanosine triphosphate cyclohydrolase 1 (GCH1)

Guanosine triphosphate cyclohydrolase 1 (GTPCH1) is the rate-limiting enzyme in the de novo biosynthesis of tetrahydrobiopterin (BH4), an essential cofactor for the synthesis of monoamine neurotransmitters such as dopamine, serotonin, and norepinephrine, as well as nitric oxide (UniProt P30793). Mutations in the GCH1 gene are primarily associated with dopa-responsive dystonia (Segawa disease) and tetrahydrobiopterin-deficient hyperphenylalaninemia, where insufficient BH4 leads to severe neurological impairment (StatPearls NBK541081). Beyond its role in metabolic and neurological disorders, GTPCH1 has emerged as a significant target in pain research; its upregulation in sensory neurons is linked to chronic neuropathic pain, and its inhibition has shown promise in reducing pain hypersensitivity (PubMed 16648851). In the cardiovascular system, GTPCH1 activity is crucial for maintaining endothelial nitric oxide synthase (eNOS) coupling, thereby preventing oxidative stress and atherosclerosis (PubMed 21640575). Consequently, therapeutic strategies involve either supplementing BH4 or its precursors in deficiency states or developing small-molecule inhibitors to manage chronic pain and inflammatory conditions (PubMed 23583988).

Other names

GTP cyclohydrolase IGTP-CH-IDYT5DYT5aGCH-1

Enzyme inhibition to reduce BH4 levels for pain management; Enzyme replacement or cofactor supplementation to restore BH4 levels in deficiency states.